Continuing their research program on coumarin derivatives as MTLDs for AD treatment, the group led by Khoobi planned to introduce a N-benzyl triazole substructure on the 3-arylcoumarin core, aiming at engaging both ChEs and 15-LOX [65], the enzyme responsible for the peroxidation of specific atoms in polyunsaturated fatty acids and found to be involved in ND development, including AD [66,67]. Here, ALOX15 is linked to Alzheimer disease.